ClinicalTrials.gg
RecruitingNCT07565311Updated May 4, 2026

Two-week Intensive Outpatient Trauma Treatment.

An interventional study of Prolonged exposure and EMDR in Posttraumatic Stress Disorder (PTSD), sponsored by Oslo University Hospital. Recruiting at 1 site in Norway. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Oslo University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Stress Disorders, Post-Traumatic with a site in Norway — 9 open to participants now, 12 under way, none of them phase 3. Stress Disorders, Post-Traumatic · Norway.

Planned enrollment
21st of 27
42 · median 96
Started
2026
the only one that year
No phase
24 of 39
8 open now
Primary completion
2027-12
later than 7 of 11 live
Registered
39th of 39
by date
Lead sponsor
3 of 39
Oslo University Hospital

Among the 39 studies in Stress Disorders, Post-Traumatic with a site in Norway, this one is the 21st largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2026, is one of 24 with no phase, reaches primary completion later than 7 of the 11 other live ones, and was the 39th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

9 of the 39 studies in Stress Disorders, Post-Traumatic with a site in Norway are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Stress Disorders, Post-Traumatic with a site in Norway, or all of them as a file.
02

Study summary

The objective of the study is to obtain knowledge about the treatment of patients who are offered intensive trauma treatment at Nydalen DPS (NDPS) and Søndre Oslo DPS (SODPS). The treatment takes place on an outpatient basis over two weeks. Up to 42 patients will be recruited. The efficacy of treatment will be investigated using validated self-report forms, which measure PTSD symptoms (PCL-5 and ITQ) and quality of life/function (WHO-5, and WSAS). The measurements will be done before the treatment and one and twelve weeks after treatment.In-depth interviews will also be conducted with up to 30 patients to investigate the outcome and any need for adjustments with focus on patients with minority backgrounds, men and patients with limited benefit. The study uses a mixed methods design, where quantitative measures and information from qualitative interviews are combined to map participants' experience, benefits and feasibility.

Read the detailed description

The objective of the study is to obtain knowledge about the treatment of patients who are offered intensive trauma treatment at Nydalen DPS (NDPS) and Søndre Oslo DPS (SODPS). The treatment takes place on an outpatient basis over two weeks. Up to 42 patients will be recruited. The efficacy of treatment will be investigated using validated self-report forms, which measure PTSD symptoms (PCL-5 and ITQ) and quality of life/function (WHO-5, and WSAS). The measurements will be done before the treatment and one and twelve weeks after treatment. In-depth interviews will also be conducted with up to 30 patients to investigate the outcome and any need for adjustments with focus on patients with minority backgrounds, males and patients with limited benefit. The study uses a mixed methods design, where quantitative measures and information from qualitative interviews are combined to map participants' experience, benefits and feasibility.

03

Conditions studied

  • Posttraumatic Stress Disorder (PTSD)

Keywords

  • Intensive trauma treatment
  • qualitative study
  • EMDR
  • Prolonged exposure
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PTSD
  • 18-65 years
  • Able to give written .

Exclusion criteria

Exclusion Criteria:

  • Active substance abuse
  • psychotic or bipolar disorder
  • organic brain disorder
  • IQ\< 70
  • Currently in a life-threating situation.
  • Serious suicide risk.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Intensive trauma treatment

    Other: Prolonged exposure and EMDR

Interventions

  • OtherProlonged exposure and EMDR

    Two-week intensive traume treatment

    Also known as: EMDR, prolonged exposure

06

What researchers measure

Primary outcomes

  1. Trauma symptom score as measured by International Trauma Questionnaire (ITQ)

    ITQ: Higher score equals higher symptom load

    Time frame: 12 weeks

Secondary outcomes

  1. Function as measured by Work and social adjustment scale (WSAS)

    Higher scores equals poorer function

    Time frame: 12 weeeks

Other outcomes

  1. Quality of life as measured by WHO-5, PTSD symptom load as measured by PCL-5

    Higher scores on WHO-5 equals better QoL, Higher scores on PCL-5 equal more PTSD symptoms

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 23 months is below that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2026
First posted
May 4, 2026
StartActual
Jan 26, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07565311
Responsible party
Julie Horgen Evensen (Principal investigator, Oslo University Hospital) — Principal investigator
First posted
May 4, 2026
Start date
Jan 26, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 4, 2026

Study contacts

Julie H Evensen, MD PhD
Contact
uxevej@ous-hf.no
004799339292
Veronica Vaage-Kowalzik, MD
Contact
UXVAAG@ous-hf.no
Julie H Evensen, MD PhD
principal investigator · Oslo University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion